Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX)

, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

covid-19
SARS
mechanical ventilation
critical illness
dexamethasone
  • 139 views
  • 21 Mar, 2022
  • 23 locations
Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

Cohort 1: The primary objectives are: To evaluate the steady-state pharmacokinetics (PK) of Atazanavir (ATV) and Darunavir (DRV) and confirm the dose of Cobicistat-boosted

antiretroviral
tenofovir
cobicistat
tuberculosis
antiretroviral agents
  • 298 views
  • 04 Oct, 2022
  • 9 locations
The Impact of Structured Caregiver Peer Support (CaPS) on ART Adherence and Viral Suppression Among Children Living With HIV in Nigeria (CaPS)

Adherence for children living with HIV is a by-proxy phenomenon dependent on caregivers (parents, relatives or unrelated guardians) who may or may not be living with HIV. The complexity of paediatric formulations and dosing for ART regimens often poses challenges for caregivers, making ART administration and achievement of viral suppression …

Accepts healthy volunteers
  • 0 views
  • 27 Oct, 2022
  • 1 location
Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

medication that contains a boosted protease inhibitor (PI) drug (such as Lopinavir or Atazanavir) (Group 2). People taking TLD and receiving medication for TB that includes the drug rifampicin (RIF

  • 40 views
  • 10 Mar, 2022
  • 14 locations
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. (PANNA)

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy …

haart
hiv antibodies
antiretroviral
antibody test
antiretroviral agents
  • 156 views
  • 07 Oct, 2022
  • 16 locations
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major teratogenic effect involving any of the Registry drugs when administered to pregnant women. Registration is voluntary and confidential with information obtained from the health care provider. A Registry-assigned identifier allows for follow-up capability. Information on subjects is …

antiretrovirals
hepatitis
antiretroviral
prenatal
antiretroviral agents
  • 70 views
  • 04 May, 2022
  • 1 location
A Long-term Follow-up of the HIV-NAT Cohort

With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients …

antiretroviral therapy
hiv viral load
AIDS
antiretroviral
antiretroviral agents
  • 2 views
  • 05 Apr, 2022
  • 1 location